5 results about "Immunodeficiency disease" patented technology

This invention relates to 2-amino-4-methylquinazoline compounds, their preparation methods, uses, and pharmaceutical compositions. Specifically, it provides a compound represented by Formula I, which is a phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor that can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, inflammation, kidney diseases, cardiovascular diseases, metabolic / endocrine disorders, or neurological diseases.

This invention relates to an IRAK4 degrading agent and its uses. This degrading agent can be used to treat or prevent diseases such as cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplant-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases, cell death-related conditions, thrombin-induced platelet aggregation, liver diseases, pathological immune conditions involving T cell activation, cardiovascular diseases, or CNS diseases.

IPEX (Immune dysregulation Polyendocrinopathy X linked) syndrome is a primary immunodeficiency caused by mutations in the gene encoding the transcription factor forkhead box P3 (FOXP3), which leads to the loss of function of thymus-derived CD4+CD25+ regulatory T (tTreg) cells. Preclinical and clinical studies suggest that T cell gene therapy approaches designed to selectively restore the repertoire of Treg cells by transfer of wild type FOXP3 gene is a promising potential cure for IPEX. However, there is still a need for a vector that can be used efficiently for the preparation of said Treg cells. The inventors thus compared 6 different lentiviral constructs according to 4 criteria (vector titers, level of transduction of human CD4+ T cells, level of expression of FOXP3 and ΔLNGFR genes, degree of correlation between both expression) and selected one construct comprising a bidirectional PGK-EF1a promoter that showed remarkable efficiency.

This invention belongs to the field of pharmaceutical technology and relates to thienopyrimidine derivatives, their preparation methods, uses, and pharmaceutical compositions. The thienopyrimidine derivatives, as shown in formula (I), are phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitors and can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, kidney diseases, cardiovascular diseases, inflammation, metabolic / endocrine dysfunction, or neurological diseases.

This invention relates to the application of asparagine in the preparation of antiviral drugs and / or drugs for treating immunodeficiency diseases, belonging to the field of biomedical technology. This invention is the first to discover that asparagine can induce TBK1 activation, increasing the expression of type I interferon in the body under viral infection conditions, enabling the body to rapidly respond to host defense mechanisms and enhance immunity when subjected to viral infection, thereby achieving a broad-spectrum antiviral effect. It also discloses a new use of asparagine as a TBK1 agonist, which can be used in the preparation of antiviral drugs, drugs for treating immunodeficiency diseases, and products for enhancing immunity. Furthermore, asparagine is a non-essential amino acid for the human body, possessing characteristics such as being green, safe, and environmentally friendly; it can be used as a functional additive in pharmaceuticals, health products, or food products.